The Connecticut state government-funded investment fund takes the antibiotics researcher to an estimated more than $43m raised, with signatories on its previous filing from Novartis' corporate venturing unit.
US-based antibiotics developer BioRelix secured $500,000 in capital on Wednesday from Connecticut Innovations (CI), a quasi-public investment entity funded by the Connecticut state legislature. CI made the investment through its Eli Whitney fund.
CI’s contribution brings BioRelix’s funding for its latest round to $4.2m, the remainder having been raised in September. The investors in that tranche were not disclosed but signatories on the filing included representatives from corporate venturing unit Novartis Venture Funds, venture capital firms New Leaf Venture…
